减轻帕罗韦德™引起的药物相互作用毒性：见解
Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an insight.
作者信息
Ta Giang H, Leong Max K
机构信息
Department of Chemistry, National Dong Hwa University, Hualien, Taiwan.
出版信息
Front Pharmacol. 2024 Nov 26;15:1496630. doi: 10.3389/fphar.2024.1496630. eCollection 2024.
Abstract
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.
摘要
帕罗韦德™（Paxlovid™）中的成分利托那韦的临床药物相互作用副作用已有记录，这凸显了探索帕罗韦德™组合中的另一种药物奈玛特韦的替代给药方法的必要性。在本研究中，使用各种模型评估了奈玛特韦的皮肤渗透潜力。预测结果表明，奈玛特韦可以通过透皮途径给药，为提高抗新冠病毒药物的疗效提供了一条有前景的途径。
相似文献
1
Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an insight.减轻帕罗韦德™引起的药物相互作用毒性：见解
Front Pharmacol. 2024 Nov 26;15:1496630. doi: 10.3389/fphar.2024.1496630. eCollection 2024.
2
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.化湿败毒颗粒联合奈玛特韦片/利托那韦片组合药物治疗奥密克戎（B.1.1.529）感染高风险因素患者的有效性和安全性：一项多臂、单中心、开放性、随机对照临床试验。
Phytomedicine. 2023 Nov;120:155025. doi: 10.1016/j.phymed.2023.155025. Epub 2023 Aug 16.
3
Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.奈玛特韦通过激活 TAS2R1 苦味受体发挥作用。
Biochem Biophys Res Commun. 2023 Nov 19;682:138-140. doi: 10.1016/j.bbrc.2023.10.001. Epub 2023 Oct 2.
4
Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes.帕罗韦德（奈玛特韦/利托那韦）诱导器官移植受者发生他克莫司毒性——关于涉及CYP3A酶的药物相互作用的综述
Curr Drug Saf. 2025;20(3):291-302. doi: 10.2174/0115748863331165240821194206.
5
Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID) with Concomitant Medications in Real-World Clinical Settings.评估药物相互作用风险：在真实临床环境中，奈玛特韦与利托那韦组合制剂（PAXLOVID）与伴随用药情况
Pathogens. 2024 Nov 30;13(12):1055. doi: 10.3390/pathogens13121055.
6
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?帕克洛维德（奈玛特韦/利托那韦）：新冠治疗的新方法？
Biomed Pharmacother. 2023 Jun;162:114367. doi: 10.1016/j.biopha.2023.114367. Epub 2023 Feb 6.
7
Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.抗 SARS-CoV-2 药物莫努匹韦和奈玛特韦/利托那韦与人药转运体的相互作用。
Int J Mol Sci. 2023 Jul 8;24(14):11237. doi: 10.3390/ijms241411237.
8
The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M and antiviral drugs (nirmatrelvir and ritonavir).帕克洛维德对抗 COVID-19 的疗效是 M 蛋白与抗病毒药物（奈玛特韦和利托那韦）紧密分子对接的结果。
Adv Med Sci. 2023 Mar;68(1):1-9. doi: 10.1016/j.advms.2022.10.001. Epub 2022 Nov 2.
9
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.利托那韦增强型奈玛特韦（帕罗韦德）与肺癌靶向治疗及支持性护理之间的药物相互作用概述
JTO Clin Res Rep. 2023 Feb;4(2):100452. doi: 10.1016/j.jtocrr.2022.100452. Epub 2022 Dec 17.
10
Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective Multicenter Observational Study.新冠治疗患者中奈玛特韦/利托那韦（帕罗韦德）的治疗药物监测：一项前瞻性多中心观察性研究的结果
Ther Drug Monit. 2025 Apr 1;47(2):258-264. doi: 10.1097/FTD.0000000000001290. Epub 2024 Dec 3.
本文引用的文献
1
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.奥密克戎 XBB 和 BA.2.86/JN.1 分支的 SARS-CoV-2 具有不同的进化特征，表现为适应性增强和抗体逃避能力提高。
Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7.
2
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy.奈玛特韦-利托那韦片（Paxlovid）抗病毒治疗后 COVID-19 反弹。
Ann Intern Med. 2023 Dec;176(12):1672-1673. doi: 10.7326/M23-2887. Epub 2023 Nov 14.
3
Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.COVID-19 患者使用奈玛特韦/利托那韦治疗后出现反弹现象导致的急性肺栓塞。
Am J Emerg Med. 2022 Nov;61:235.e5-235.e6. doi: 10.1016/j.ajem.2022.08.012. Epub 2022 Aug 6.
4
Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.老年人使用多种药物时与奈玛特韦-利托那韦的药物相互作用。
JAMA Netw Open. 2022 Jul 1;5(7):e2220184. doi: 10.1001/jamanetworkopen.2022.20184.
5
Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病复发患者经奈玛特韦/利托那韦治疗后的病毒学和免疫学特征。
Clin Infect Dis. 2023 Feb 8;76(3):e530-e532. doi: 10.1093/cid/ciac496.
6
In Silico Prediction of Skin Permeability Using a Two-QSAR Approach.使用双定量构效关系方法对皮肤渗透性进行计算机模拟预测。
Pharmaceutics. 2022 Apr 28;14(5):961. doi: 10.3390/pharmaceutics14050961.
7
Emerging small molecule antivirals may fit neatly into COVID-19 treatment.新兴的小分子抗病毒药物可能恰好适用于新冠病毒病的治疗。
Drugs Ther Perspect. 2022;38(3):112-126. doi: 10.1007/s40267-022-00897-8. Epub 2022 Feb 28.
8
Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.新冠病毒感染的移植受者使用帕罗韦德治疗的特殊注意事项
Am J Kidney Dis. 2022 Apr;79(4):480-482. doi: 10.1053/j.ajkd.2022.01.001. Epub 2022 Jan 12.
9
Transdermal drug delivery systems for fighting common viral infectious diseases.用于对抗常见病毒性传染病的经皮药物传递系统。
Drug Deliv Transl Res. 2021 Aug;11(4):1498-1508. doi: 10.1007/s13346-021-01004-6. Epub 2021 May 22.
10
Enhancing Permeation of Drug Molecules Across the Skin via Delivery in Nanocarriers: Novel Strategies for Effective Transdermal Applications.通过纳米载体递送增强药物分子经皮渗透：有效透皮应用的新策略
Front Bioeng Biotechnol. 2021 Mar 29;9:646554. doi: 10.3389/fbioe.2021.646554. eCollection 2021.
Zotero 插件